{
  "symbol": "SAGE",
  "company_name": "Sage Therapeutic Com",
  "ir_website": "https://investor.sagerx.com/",
  "structured_data": [
    {
      "section_name": "Press Releases & Statements",
      "links": [
        {
          "title": "Sage Therapeutics Announces Dr. Jeff Jonas to Retire from Board of Directors",
          "url": "https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-dr-jeff-jonas-retire-board-directors",
          "content": "[Skip to content](#lfg-main-content)\n\nWe have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our [Privacy Policy](https://www.sagerx.com/privacy-policy) and [Terms of Use](https://www.sagerx.com/terms-of-use) . \n\n[ACCEPT]()\n\n[ ![Sage Therapeutics](https://assets.sagerx.com/sagerxcom/wp-content/themes/sagerx-v3/assets/img/logo-sagerx.svg) ](https://www.sagerx.com) Menu\n\nSearch Search open search box close search box Close Search\n\n![](/sites/g/files/knoqqb72001/themes/site/nir_pid931/client/images/Sage_Banner_2.png)\n\n# Investors & Media\n\n##  News \n\n![](/sites/g/files/knoqqb72001/themes/site/nir_pid931/client/images/Brain1440x325d.jpg)\n\n[Back](#)\n\nNovember 26, 2024 \n\n# \n\nSage Therapeutics Announces Dr. Jeff Jonas to Retire from Board of Directors\n\n**CAMBRIDGE, Mass. –** **November 26, 2024 --** Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Jeff Jonas, MD will retire from the Company’s Board of Directors as of December 1, 2024. The Company has initiated a search for a new director. Dr. Jonas was CEO at Sage from 2013 to 2020, Chief Innovation Officer from 2020 to 2022, and has served on the Board since 2013.\n\nDr. Jonas is currently a Partner at Cure Ventures, bringing over two decades of experience in R&D leadership and CNS drug discovery to his role. Before joining Cure, Dr. Jonas was CEO, President, and Director at ABIO-X, a life science incubator focused on transformative medicines. Prior to ABIO-X and Sage Therapeutics, he was President of the Regenerative Medicine Division at Shire Pharmaceuticals, where he directed strategy for marketed products and new pipeline development. Earlier in his career, Dr. Jonas was EVP at ISIS (Ionis) Pharmaceuticals and held senior roles at Forest Laboratories and Upjohn.\n\nDr. Jonas has authored over 300 peer-reviewed publications, chapters, and presentations; and holds multiple patents. He earned a BA from Amherst College, an MD from Harvard Medical School, and completed a psychiatry residency at Harvard, where he was Chief Resident of Psychopharmacology at McLean Hospital. He currently serves on the board of Generation Bio and is Chairman of Noema Therapeutics and Kenai Therapeutics.\n"
        },
        {
          "title": "Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference",
          "url": "https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-present-piper-sandler-36th-annual-healthcare",
          "content": "[Skip to content](#lfg-main-content)\n\nWe have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our [Privacy Policy](https://www.sagerx.com/privacy-policy) and [Terms of Use](https://www.sagerx.com/terms-of-use) . \n\n[ACCEPT]()\n\n[ ![Sage Therapeutics](https://assets.sagerx.com/sagerxcom/wp-content/themes/sagerx-v3/assets/img/logo-sagerx.svg) ](https://www.sagerx.com) Menu\n\nSearch Search open search box close search box Close Search\n\n![](/sites/g/files/knoqqb72001/themes/site/nir_pid931/client/images/Sage_Banner_2.png)\n\n# Investors & Media\n\n##  News \n\n![](/sites/g/files/knoqqb72001/themes/site/nir_pid931/client/images/Brain1440x325d.jpg)\n\n[Back](#)\n\nNovember 26, 2024 \n\n# \n\nSage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference\n\nCAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2024-- Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:00 a.m. ET in New York, NY. \n\nA live webcast of the presentation can be accessed on the Investor page of Sage’s website at [investor.sagerx.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.sagerx.com%2F&esheet=54158137&newsitemid=20241125192277&lan=en-US&anchor=investor.sagerx.com&index=1&md5=7d8d8b9cac4f0730ff7fe09899f0a989). A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. \n\n**About Sage Therapeutics **Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at [www.sagerx.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sagerx.com%2F&esheet=54158137&newsitemid=20241125192277&lan=en-US&anchor=www.sagerx.com&index=2&md5=b72c186b212bd082b12bdabd1800a128) or engage with us on [Facebook](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FThisIsSage&esheet=54158137&newsitemid=20241125192277&lan=en-US&anchor=Facebook&index=3&md5=00ae0d1f604538a43ebbe63168de740e), [LinkedIn](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsage-therapeutics&esheet=54158137&newsitemid=20241125192277&lan=en-US&anchor=LinkedIn&index=4&md5=d3fdf53c39b35d1bb48ad02cbe9d04e0), [Instagram](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fsagebiotech%2F&esheet=54158137&newsitemid=20241125192277&lan=en-US&anchor=Instagram&index=5&md5=325b6b79a166367aceb10d6a9ff8456e), and [X](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FSageBiotech&esheet=54158137&newsitemid=20241125192277&lan=en-US&anchor=X&index=6&md5=240256eee680929592a6636323ac52da). \n\n![](https://cts.businesswire.com/ct/CT?id=bwnews&sty=20241125192277r1&sid=acqr8&distro=nx&lang=en)\n\nView source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20241125192277/en/>\n\n**Investor:** Katie Plante Katie.Plante@sagerx.com\n\n**Media:** Francesca Dellelci Francesca.Dellelci@sagerx.com\n\nSource: Sage Therapeutics, Inc.\n"
        }
      ]
    }
  ]
}